---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091205"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:40:36.042247+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neumora Q2 net loss $58.7M; Phase 3 MDD data on track for Q4 2024

## Summary
- Cash $371.6M as of June 30, 2024, expected to fund operations into 2026.
- R&D expense $48.6M (up from $32.8M); G&A $15.2M (up from $9.3M).
- Topline data from KOASTAL-1 Phase 3 study of navacaprant in MDD expected Q4 2024.
- Phase 2 trial for navacaprant in bipolar depression initiated; Phase 1b of NMRA-511 in Alzheimer's agitation started.
- NMRA-266 study on clinical hold; additional M4 PAM IND submission expected first half 2025.

## SEC filing metadata
- accession: 0000950170-24-091205
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000095017024091205/0000950170-24-091205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000095017024091205/nmra-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091205
- JSON: https://secwatch.observer/filing/0000950170-24-091205.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.